Carbonic Anhydrase 9 - Pipeline Review, H2 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Carbonic Anhydrase 9 - Pipeline Review, H2 2019
According to the recently published report Carbonic Anhydrase 9 - Pipeline Review, H2 2019; Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme encoded by the CA9 gene. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid.
The report Carbonic Anhydrase 9 - Pipeline Review, H2 2019 outlays comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Breast Cancer, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.
Scope
- The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)
- The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
According to the recently published report Carbonic Anhydrase 9 - Pipeline Review, H2 2019; Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Carbonic anhydrase 9 (CA9/CAIX) is an enzyme encoded by the CA9 gene. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid.
The report Carbonic Anhydrase 9 - Pipeline Review, H2 2019 outlays comprehensive information on the Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Breast Cancer, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.
Scope
- The report provides a snapshot of the global therapeutic landscape for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)
- The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Overview
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
EstryX Pharma Ltd
Kalgene Pharmaceuticals Inc
SignalChem Lifesciences Corp
Telix Pharmaceuticals Ltd
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drug Profiles
(acetazolamide + temozolomide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESE-15-ol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CA9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TX-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CA9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Dormant Products
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Product Development Milestones
Featured News & Press Releases
Aug 30, 2019: Telix Pharmaceuticals to launch Japanese Renal Cancer Imaging Study
Aug 20, 2019: First Australian patient dosed in ZIRCON phase III trial
Jul 19, 2019: Telix Pharmaceuticals: Japanese regulatory update for renal cancer imaging program
Jul 15, 2019: Telix Pharmaceuticals reports positive phase III meeting with the FDA
Jun 13, 2019: Telix Pharmaceuticals and Eczacibasi-Monrol sign manufacturing and distribution agreement
Jun 05, 2019: Heidelberg Pharma receives milestone payment from partner Telix
Mar 20, 2019: cGMP manufacturing of TLX250 complete
Oct 23, 2018: Telix commences ZIRCON phase III renal cancer imaging trial
Oct 17, 2018: Telix Selects RTM to Manufacture Kidney Imaging Program in Europe
Oct 15, 2018: Interim analysis of 89 Zr-TLX250-CDx bridging study (ZIR - DOSE) demonstrates significantly improved patient dosimetry
Oct 15, 2018: Telix and Cyclotek Enter into Manufacturing Partnership for Kidney Cancer Imaging
Aug 23, 2018: Heidelberg Pharma: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Jul 26, 2018: Telix Pharmaceuticals and JFE Progress japanese manufacturing partnership
Jun 25, 2018: Telix and Isologic conclude manufacturing agreement for North America
May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up Partner
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Akshaya Bio Inc, H2 2019
Pipeline by EstryX Pharma Ltd, H2 2019
Pipeline by Kalgene Pharmaceuticals Inc, H2 2019
Pipeline by SignalChem Lifesciences Corp, H2 2019
Pipeline by Telix Pharmaceuticals Ltd, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Overview
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
EstryX Pharma Ltd
Kalgene Pharmaceuticals Inc
SignalChem Lifesciences Corp
Telix Pharmaceuticals Ltd
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drug Profiles
(acetazolamide + temozolomide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESE-15-ol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CA9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrase IX for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STX-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TX-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CA9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Dormant Products
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Product Development Milestones
Featured News & Press Releases
Aug 30, 2019: Telix Pharmaceuticals to launch Japanese Renal Cancer Imaging Study
Aug 20, 2019: First Australian patient dosed in ZIRCON phase III trial
Jul 19, 2019: Telix Pharmaceuticals: Japanese regulatory update for renal cancer imaging program
Jul 15, 2019: Telix Pharmaceuticals reports positive phase III meeting with the FDA
Jun 13, 2019: Telix Pharmaceuticals and Eczacibasi-Monrol sign manufacturing and distribution agreement
Jun 05, 2019: Heidelberg Pharma receives milestone payment from partner Telix
Mar 20, 2019: cGMP manufacturing of TLX250 complete
Oct 23, 2018: Telix commences ZIRCON phase III renal cancer imaging trial
Oct 17, 2018: Telix Selects RTM to Manufacture Kidney Imaging Program in Europe
Oct 15, 2018: Interim analysis of 89 Zr-TLX250-CDx bridging study (ZIR - DOSE) demonstrates significantly improved patient dosimetry
Oct 15, 2018: Telix and Cyclotek Enter into Manufacturing Partnership for Kidney Cancer Imaging
Aug 23, 2018: Heidelberg Pharma: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Jul 26, 2018: Telix Pharmaceuticals and JFE Progress japanese manufacturing partnership
Jun 25, 2018: Telix and Isologic conclude manufacturing agreement for North America
May 02, 2018: Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up Partner
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Akshaya Bio Inc, H2 2019
Pipeline by EstryX Pharma Ltd, H2 2019
Pipeline by Kalgene Pharmaceuticals Inc, H2 2019
Pipeline by SignalChem Lifesciences Corp, H2 2019
Pipeline by Telix Pharmaceuticals Ltd, H2 2019
Dormant Projects, H2 2019
List Of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
RELATED REPORTS
Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) - Drugs in Development, 2021
Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) - Drugs in Development, 2021Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or
View ReportCarbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drugs in Development, 2021
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drugs in Development,
View ReportCarbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) - Drugs in Development, 2021
Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) - Drugs in Development, 2021Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or
View ReportCarbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drugs in Development, 2021
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drugs in Development,
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
